- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01598883
Understanding "Heparin Resistance" in Cardiac Surgery
Understanding "Heparin Resistance" in Cardiac Surgery: Altered Heparin Responsiveness and Its Association With Acute Inflammatory Reactions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study uses a prospective, randomized, open-label cross-over design to evaluate the responses to recombinant human AT (rhAT) and/or supplemental heparin for restoration of heparin-responsiveness in the presence of biomarkers of acute inflammation, so called acute phase reactants. Our ultimate goal is, of course, to apply this knowledge to optimize perioperative management of anticoagulation in patients undergoing cardiopulmonary bypass.
We will first identify enrolled patients with altered heparin responsiveness (AHR) as defined by an ACT < 450 seconds (the MGH standard target ACT after the initial dose of heparin for CPB). Patients who achieve an ACT > 450 sec will not enter the randomization phase of the study, their participation in the study will be complete and their routine clinical care will continue unaltered. Those with AHR (post-heparin ACT < 450 sec) will be randomized to receive either supplemental heparin or supplemental AT. Those that fail to achieve an adequate ACT after the first supplementation will cross-over to receive the alternate supplement. Blood samples (totaling at most 20 ml) will be taken at each step to measure heparin level, AT level, AT activity. Once a patient is placed onto cardiopulmonary bypass their participation in the study will be complete.
By design, this study replicates routine clinical management of heparin anticoagulation for cardiopulmonary bypass at the MGH. Most patients (80%) coming to cardiac surgery who will undergo CPB respond adequately to a routine initial bolus dose of heparin (ACT > 450 after 350 U/kg); as noted, subjects in this study that achieve the target ACT will be managed according to routine clinical practice without further testing or intervention.
Under routine care, patients with an inadequate initial response to heparin receive either supplemental heparin (150 U/kg) or pooled human antithrombin (1000 Units), or both. In this study, subjects with inadequate heparin response (ACT < 450) after the initial heparin bolus, will be randomly assigned to two comparison groups; half will receive supplemental heparin (150 U/kg) and half will receive AT (1000 IU). Subjects who fail to respond to their assigned first intervention will cross-over to receive the alternate intervention.
Some subjects may not achieve the target ACT despite receiving both supplemental heparin and AT comprising a group of patients with "true heparin resistance" whose coagulation profiles can be further characterized to better understand the mechanisms of the resistance. These subjects will be considered to have completed the study even though they are not yet on cardiopulmonary bypass and will be managed according to the best clinical judgment of their physicians. They may receive additional heparin, additional AT, fresh-frozen plasma, or any combination of these. These patients may be at risk for thrombotic complications during the post-operative period. Accordingly, when clinically appropriate, these individuals may be referred for further evaluation of their coagulation status, but these evaluations will not be done as part of this study.
This is a pathophysiological risk-factor association study that seeks to better understand the phenomenon of altered heparin responsiveness. Accordingly, there is no specific study endpoint apart from achieving an ACT of > 450 sec. In all enrolled subjects we will measure the levels of three acute phase reactants, Factor VIII, fibrinogen and CRP, heparin levels (anti Xa), AT level (immunofixation) and AT activity after the initial heparin dose. For all subjects who do not achieve and ACT of > 450 we will also measure additional heparin levels (anti Xa), AT level (immunofixation), and AT activity after each intervention in the randomization/crossover phase. The total amount of blood taken for the research-specific laboratory test is less than 20 ml.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients scheduled for elective cardiac or aortic surgery requiring CPB for which heparin will be used for systemic anticoagulation
- Patients scheduled for urgent surgery who are hemodynamically stable and capable of giving voluntary consent
- Patients with platelet factor 4 antibody positivity (antiPF4+) for whom heparin anticoagulation will be used
Exclusion Criteria:
- Patients for whom heparin will not be used for anticoagulation
- Patients with known congenital AT-deficiency
- Patients with known goat milk allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: ACT after initial heparin bolus less than 450
If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
|
150 U/kg
Other Names:
1000 IU
Other Names:
|
Active Comparator: ACT after first intervention less than 450
|
150 U/kg
Other Names:
1000 IU
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Altered Heparin Responsivness (AHR)
Time Frame: Participants will be followed from the administration of the initial heparin bolus to being placed on CPB, an average of 15 minutes.
|
We will first identify patients with AHR as defined by an ACT <450 seconds (the MGH standard target ACT after the initial dose of heparin for CPB).
We will evaluate the hypothesis that AHR may be directly related to, modulated or mediated by interactions between heparin, antithrombin (AT), the heparin-AT complex, and one or more acute phase proteins.
|
Participants will be followed from the administration of the initial heparin bolus to being placed on CPB, an average of 15 minutes.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
"True Heparin Resistance"
Time Frame: Patients will be followed from the administration of the initial heparin bolus to being placed on CPB, an average of 15 minutes.
|
Those with AHR (post-heparin ACT < 450 sec) will be randomized to receive either supplemental heparin or supplemental AT.
Those that fail to achieve an adequate ACT after the first supplementation will cross-over to receive the alternate supplement.
If patient still fails to achieve an adequate ACT after both supplementations they will be classified as having "True Heparin Resistance".
|
Patients will be followed from the administration of the initial heparin bolus to being placed on CPB, an average of 15 minutes.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Greg Koski, MD, PhD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Altered Heparin Responsiveness
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiopulmonary Bypass
-
Baxter Healthcare CorporationCompletedCardiopulmonary Bypass | Sternotomy | Cardiac Surgery Requiring Cardiopulmonary Bypass and Median SternotomyUnited States
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCardiopulmonary Bypass | Coronary Artery Bypass GraftingChina
-
University Hospital, GhentCompletedCardiopulmonary Bypass
-
Aristotle University Of ThessalonikiCompletedHeparin and Protamine Titration in Cardiac Surgery Under Minimal Invasive Extracorporeal CirculationCardiopulmonary BypassGreece
-
University Medical Centre LjubljanaSlovenian Research AgencyCompleted
-
Ulf BorgMedtronic - MITGCompletedCardiopulmonary BypassChina
-
Emory UniversityChildren's Research Oversight Committee FundsCompletedCardiopulmonary BypassUnited States
-
University of Texas Southwestern Medical CenterChildren's Medical Center DallasUnknownCardiopulmonary BypassUnited States
-
Loma Linda UniversityCompletedCardiopulmonary BypassUnited States
-
Umeå UniversityCompletedCardiopulmonary BypassSweden
Clinical Trials on Heparin
-
San Filippo Neri General HospitalUniversity of Roma La SapienzaUnknownAngina, Unstable | Stable Angina | Non-ST Elevation (NSTEMI) Myocardial InfarctionItaly
-
Robert F. JamesIndiana University School of MedicineSuspendedNeurobehavioral Manifestations | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, Intracranial | Intracranial Aneurysm | Heparin-induced Thrombocytopenia Type IIUnited States
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownRenal Failure | HemodialysisItaly
-
Christine RibicMcMaster University; LEO PharmaCompleted
-
Regado Biosciences, Inc.CompletedAcute Coronary Syndrome (ACS)United States, Canada, Germany, France
-
The University of Texas Health Science Center at...WithdrawnThrombosis | Anticoagulants | Infant, PrematureUnited States
-
University of OklahomaRecruitingRecurrent Urinary Tract InfectionsUnited States
-
Azidus BrasilSuspendedChronic Renal FailureBrazil